Solid Biosciences (SLDB)

• Market cap: $276M
• 1 day: 8.52%
• 5 days: -6.50%
• 1 month: -10.54%
• 3 months: -0.30%
• 6 months: -42.23%
• Year to date: -15.13%
• 1 year: -62.68%
• 5 years: -90.49%
• 10 years: -99.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Employees: 100

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2,279% more call options, than puts

Call options by funds: $2.38M | Put options by funds: $100K

75% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 20

1.94% less ownership

Funds ownership: 92.86% [Q3] → 90.92% (-1.94%) [Q4]

2% less funds holding

Funds holding: 92 [Q3] → 90 (-2) [Q4]

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

42% less capital invested

Capital invested by funds: $250M [Q3] → $145M (-$105M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 232% upside
• Avg. target: $15.50 368% upside
• High target: $20 504% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Anupam Rama 22% 1-year accuracy 13 / 60 met price target	232% upside $11	Overweight Maintained	13 Mar 2025
HC Wainwright & Co. Arthur He 6% 1-year accuracy 2 / 32 met price target	504% upside $20	Buy Maintained	10 Mar 2025
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 59 met price target	383% upside $16	Buy Maintained	7 Mar 2025
Citizens Capital Markets Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target	353% upside $15	Market Outperform Reiterated	7 Mar 2025